236 related articles for article (PubMed ID: 26670587)
1. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
Fiore M; Trodella L; Valeri S; Borzomati D; Floreno B; Ippolito E; Trecca P; Trodella LE; D'Angelillo RM; Ramella S; Coppola R
Radiat Oncol; 2015 Dec; 10():255. PubMed ID: 26670587
[TBL] [Abstract][Full Text] [Related]
2. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
3. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
4. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma.
Wilkowski R; Thoma M; Dühmke E; Rau HG; Heinemann V
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):768-72. PubMed ID: 14967432
[TBL] [Abstract][Full Text] [Related]
10. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Arnoletti JP; Frolov A; Eloubeidi M; Keene K; Posey J; Wood T; Greeno E; Jhala N; Varadarajulu S; Russo S; Christein J; Oster R; Buchsbaum DJ; Vickers SM
Cancer Chemother Pharmacol; 2011 Apr; 67(4):891-7. PubMed ID: 20589377
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Goldstein D; Van Hazel G; Walpole E; Underhill C; Kotasek D; Michael M; Shapiro J; Davies T; Reece W; Harvey J; Spry N
Br J Cancer; 2007 Aug; 97(4):464-71. PubMed ID: 17653074
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
[TBL] [Abstract][Full Text] [Related]
17. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Schauer R; Wagner A; Heinemann V
World J Surg; 2004 Oct; 28(10):1011-8. PubMed ID: 15573257
[TBL] [Abstract][Full Text] [Related]
18. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
19. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Spry N; Harvey J; Macleod C; Borg M; Ngan SY; Millar JL; Graham P; Zissiadis Y; Kneebone A; Carroll S; Davies T; Reece WH; Iacopetta B; Goldstein D
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1438-46. PubMed ID: 18164859
[TBL] [Abstract][Full Text] [Related]
20. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
